ABIVAX Société Anonyme (ABVX.PA)
EUR 7.48
(2.89%)
EUR 7.48
(2.89%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -127.37 Million EUR | -133.02% |
| 2022 | -56.64 Million EUR | -8.54% |
| 2021 | -52.18 Million EUR | -31.8% |
| 2020 | -39.59 Million EUR | -18.99% |
| 2019 | -33.27 Million EUR | -74.13% |
| 2018 | -19.1 Million EUR | -35.05% |
| 2017 | -14.15 Million EUR | 22.41% |
| 2016 | -18.23 Million EUR | 0.1% |
| 2015 | -18.25 Million EUR | -106.11% |
| 2014 | -8.85 Million EUR | -19.73% |
| 2013 | -7.39 Million EUR | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q2 | -79.99 Million EUR | 0.0% |
| 2023 Q2 | -39.53 Million EUR | 0.0% |
| 2023 FY | -131.99 Million EUR | -133.02% |
| 2023 Q4 | -90.17 Million EUR | 0.0% |
| 2022 Q2 | -18.62 Million EUR | 0.0% |
| 2022 Q4 | -38.02 Million EUR | 0.0% |
| 2022 FY | -56.64 Million EUR | -8.54% |
| 2021 FY | -52.18 Million EUR | -31.8% |
| 2021 Q2 | -26.53 Million EUR | 0.0% |
| 2021 Q4 | -25.68 Million EUR | 0.0% |
| 2020 Q2 | -16.21 Million EUR | 0.0% |
| 2020 Q4 | -23.38 Million EUR | 0.0% |
| 2020 FY | -39.59 Million EUR | -18.99% |
| 2019 Q2 | -17.2 Million EUR | 0.0% |
| 2019 FY | -33.27 Million EUR | -74.13% |
| 2019 Q4 | -16.06 Million EUR | 0.0% |
| 2018 FY | -19.1 Million EUR | -35.05% |
| 2018 Q4 | -10.54 Million EUR | 0.0% |
| 2018 Q2 | -8.56 Million EUR | 0.0% |
| 2017 FY | -14.15 Million EUR | 22.41% |
| 2017 Q4 | -6.74 Million EUR | 0.0% |
| 2017 Q2 | -7.4 Million EUR | 0.0% |
| 2016 FY | -18.23 Million EUR | 0.1% |
| 2016 Q2 | -10.61 Million EUR | 0.0% |
| 2016 Q4 | -7.61 Million EUR | 0.0% |
| 2015 Q2 | -8.1 Million EUR | 0.0% |
| 2015 FY | -18.25 Million EUR | -106.11% |
| 2015 Q4 | -10.14 Million EUR | 0.0% |
| 2014 Q4 | -4.29 Million EUR | -199900.0% |
| 2014 FY | -8.85 Million EUR | -19.73% |
| 2014 Q1 | -378.50 EUR | 0.0% |
| 2014 Q2 | -757 Thousand EUR | -199900.0% |
| 2014 Q3 | -2148.50 EUR | 99.72% |
| 2013 FY | -7.39 Million EUR | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| ABIONYX Pharma SA | -3.41 Million EUR | -3633.177% |
| Adocia SA | -17.62 Million EUR | -622.824% |
| Aelis Farma SA | -6.46 Million EUR | -1871.46% |
| Biophytis S.A. | -14.33 Million EUR | -788.69% |
| Advicenne S.A. | -6.45 Million EUR | -1872.681% |
| genOway Société anonyme | 2.06 Million EUR | 6267.445% |
| IntegraGen SA | -183.77 Thousand EUR | -69212.728% |
| Medesis Pharma S.A. | -4.22 Million EUR | -2911.722% |
| Neovacs S.A. | -6.9 Million EUR | -1744.012% |
| NFL Biosciences SA | -4.43 Million EUR | -2775.032% |
| Plant Advanced Technologies SA | -778.23 Thousand EUR | -16267.251% |
| Quantum Genomics Société Anonyme | -3.13 Million EUR | -3960.111% |
| Sensorion SA | -22.31 Million EUR | -470.921% |
| Theranexus Société Anonyme | -7.64 Million EUR | -1566.423% |
| TME Pharma N.V. | -5.62 Million EUR | -2164.865% |
| Valbiotis SA | -7.16 Million EUR | -1678.994% |
| TheraVet SA | -2.17 Million EUR | -5756.074% |
| Valerio Therapeutics Société anonyme | -20.28 Million EUR | -527.839% |
| argenx SE | -417.15 Million EUR | 69.465% |
| BioSenic S.A. | -7.04 Million EUR | -1709.318% |
| Celyad Oncology SA | -8.45 Million EUR | -1406.161% |
| DBV Technologies S.A. | -85.24 Million EUR | -49.421% |
| Galapagos NV | -88.26 Million EUR | -44.314% |
| Genfit S.A. | -26.58 Million EUR | -379.217% |
| GeNeuro SA | -14.35 Million EUR | -787.186% |
| Hyloris Pharmaceuticals SA | -15.99 Million EUR | -696.448% |
| Innate Pharma S.A. | -12.66 Million EUR | -905.415% |
| Inventiva S.A. | -102.7 Million EUR | -24.016% |
| MaaT Pharma SA | -19.94 Million EUR | -538.7% |
| MedinCell S.A. | -20.97 Million EUR | -507.217% |
| Nanobiotix S.A. | -26.77 Million EUR | -375.656% |
| Onward Medical N.V. | -35.46 Million EUR | -259.18% |
| Oryzon Genomics S.A. | -4.54 Million EUR | -2699.969% |
| OSE Immunotherapeutics SA | -22.98 Million EUR | -454.146% |
| Oxurion NV | -12.11 Million EUR | -951.825% |
| Pharming Group N.V. | -4.87 Million EUR | -2510.408% |
| Poxel S.A. | -28.76 Million EUR | -342.831% |
| GenSight Biologics S.A. | -29.69 Million EUR | -328.933% |
| Transgene SA | -30.01 Million EUR | -324.417% |
| Financière de Tubize SA | -2.14 Million EUR | -5841.117% |
| UCB SA | 604 Million EUR | 121.089% |
| Valneva SE | -82.08 Million EUR | -55.172% |
| Vivoryon Therapeutics N.V. | -28.83 Million EUR | -341.71% |